Table 1 Demographical and clinical characteristics of the 99 IBD patients who answered the survey.
Features | IBD patients (n = 99) |
|---|---|
Age, mean ± sd | 38.7 ± 13.9 |
Sex, n (%) | |
Male | 57 (57.5%) |
Female | 42 (42.4%) |
Type of disease, n (%) | |
Crohn’s disease | 54 (54.5%) |
Ulcerative Colitis | 45 (45.4%) |
Disease stage, n (%) | |
Active | 29 (29.2%) |
Remission | 70 (70.7%) |
Duration of disease, n (%) | |
< 5 years | 28 (28.2%) |
5–10 years | 22 (22.2%) |
> 10 years | 49 (49.4%) |
Weight, mean ± sd | 67.2 ± 13.8 |
BMI | 23.02 ± 3.5 |
Pharmacological therapy on-going, n (%) | |
Biologic therapies | 44 (44.4%) |
Adalimumab | 9 (9%) |
Vedolizumab | 11 (11%) |
Ustekinumab | 8 (8%) |
Infliximab | 16 (16%) |
Steroids | 3 (3%) |
Mesalazine | 26 (25%) |
Azathioprine | 17 (17%) |
